Limits...
Satraplatin in the treatment of hormone-refractory metastatic prostate cancer.

Armstrong AJ, George DJ - Ther Clin Risk Manag (2007)

Bottom Line: As men who have progressed after docetaxel and prednisone have an expected median survival of approximately 12 months, there is great opportunity for improved palliation in this disease.Investigation of predictors of platinum sensitivity and the use of satraplatin in patients with neuroendocrine subsets of metastatic prostate cancer may be warranted given the advances in biomarker and genomic technology and the known sensitivity of small cell cancers to platinum agents.Further study of satraplatin alone or in combination with docetaxel or other molecular and chemotherapeutic agents seems warranted to improve on current outcomes.

View Article: PubMed Central - PubMed

ABSTRACT
Satraplatin is an orally bioavailable platinum chemotherapeutic agent under development for several cancer types, including hormone-refractory prostate cancer (HRPC). Satraplatin is being developed for the treatment of men with chemorefractory HRPC for several reasons: 1) relative ease of administration, 2) potential lack of cross-resistance with other platinum agents, 3) clinical benefits seen in early studies of HRPC, and 4) an unmet need in this patient population after docetaxel failure. As men who have progressed after docetaxel and prednisone have an expected median survival of approximately 12 months, there is great opportunity for improved palliation in this disease. Satraplatin may provide a palliative benefit for these men in terms of progression-free survival according to the most recent analyses of the phase III SPARC trial comparing satraplatin and prednisone to prednisone alone in the second-line setting for HRPC, and is currently under USFDA review for this indication. Whether satraplatin and prednisone offer an advantage over docetaxel retreatment or other cytotoxic agents in this setting is an unanswered question and worthy of study. Investigation of predictors of platinum sensitivity and the use of satraplatin in patients with neuroendocrine subsets of metastatic prostate cancer may be warranted given the advances in biomarker and genomic technology and the known sensitivity of small cell cancers to platinum agents. Further study of satraplatin alone or in combination with docetaxel or other molecular and chemotherapeutic agents seems warranted to improve on current outcomes.

No MeSH data available.


Related in: MedlinePlus

Progression-free survival in phase III trial of satraplatin and prednisone vs. prednisone alone in HRPC, terminated early after 50 patients. Reproduced with permission from Sternberg CN, Whelan P, Hetherington P, et al. 2005. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology, 68:2–9 Copyright © 2005 S. Karger AG.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376074&req=5

fig2: Progression-free survival in phase III trial of satraplatin and prednisone vs. prednisone alone in HRPC, terminated early after 50 patients. Reproduced with permission from Sternberg CN, Whelan P, Hetherington P, et al. 2005. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology, 68:2–9 Copyright © 2005 S. Karger AG.

Mentions: In 2005, Sternberg et al published the results of an aborted phase III EORTC study of satraplatin and prednisone compared to prednisone alone in the first-line setting in HRPC (Sternberg et al 2005). Fifty subjects out of an intended 380 were analyzed before the study was terminated by the sponsoring company (Bristol-Myers-Squibb) due to a variety of reasons. The dose of satraplatin was 100 mg/m2 day 1–5, repeated every 5 weeks along with prednisone 10 mg twice daily, with up to 8 cycles administered with prophylactic anti-emetics. Despite the small numbers, a greater proportion of satraplatin-treated subjects experienced prostrate-specific antigen (PSA) declines over 50% (33.3% vs 8.7%), and progression-free survival favored satraplatin (5.2 vs 2.7 months, HR 0.50 and 95% CI 0.28–0.92, see Figure 2). Additionally, overall survival favored satraplatin by 3 months (14.9 vs 11.9 months, p = 0.58) but did not meet statistical significance (Sternberg et al 2005). Based on these results, satraplatin was revived by GPC Biotech and its development continued.


Satraplatin in the treatment of hormone-refractory metastatic prostate cancer.

Armstrong AJ, George DJ - Ther Clin Risk Manag (2007)

Progression-free survival in phase III trial of satraplatin and prednisone vs. prednisone alone in HRPC, terminated early after 50 patients. Reproduced with permission from Sternberg CN, Whelan P, Hetherington P, et al. 2005. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology, 68:2–9 Copyright © 2005 S. Karger AG.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376074&req=5

fig2: Progression-free survival in phase III trial of satraplatin and prednisone vs. prednisone alone in HRPC, terminated early after 50 patients. Reproduced with permission from Sternberg CN, Whelan P, Hetherington P, et al. 2005. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology, 68:2–9 Copyright © 2005 S. Karger AG.
Mentions: In 2005, Sternberg et al published the results of an aborted phase III EORTC study of satraplatin and prednisone compared to prednisone alone in the first-line setting in HRPC (Sternberg et al 2005). Fifty subjects out of an intended 380 were analyzed before the study was terminated by the sponsoring company (Bristol-Myers-Squibb) due to a variety of reasons. The dose of satraplatin was 100 mg/m2 day 1–5, repeated every 5 weeks along with prednisone 10 mg twice daily, with up to 8 cycles administered with prophylactic anti-emetics. Despite the small numbers, a greater proportion of satraplatin-treated subjects experienced prostrate-specific antigen (PSA) declines over 50% (33.3% vs 8.7%), and progression-free survival favored satraplatin (5.2 vs 2.7 months, HR 0.50 and 95% CI 0.28–0.92, see Figure 2). Additionally, overall survival favored satraplatin by 3 months (14.9 vs 11.9 months, p = 0.58) but did not meet statistical significance (Sternberg et al 2005). Based on these results, satraplatin was revived by GPC Biotech and its development continued.

Bottom Line: As men who have progressed after docetaxel and prednisone have an expected median survival of approximately 12 months, there is great opportunity for improved palliation in this disease.Investigation of predictors of platinum sensitivity and the use of satraplatin in patients with neuroendocrine subsets of metastatic prostate cancer may be warranted given the advances in biomarker and genomic technology and the known sensitivity of small cell cancers to platinum agents.Further study of satraplatin alone or in combination with docetaxel or other molecular and chemotherapeutic agents seems warranted to improve on current outcomes.

View Article: PubMed Central - PubMed

ABSTRACT
Satraplatin is an orally bioavailable platinum chemotherapeutic agent under development for several cancer types, including hormone-refractory prostate cancer (HRPC). Satraplatin is being developed for the treatment of men with chemorefractory HRPC for several reasons: 1) relative ease of administration, 2) potential lack of cross-resistance with other platinum agents, 3) clinical benefits seen in early studies of HRPC, and 4) an unmet need in this patient population after docetaxel failure. As men who have progressed after docetaxel and prednisone have an expected median survival of approximately 12 months, there is great opportunity for improved palliation in this disease. Satraplatin may provide a palliative benefit for these men in terms of progression-free survival according to the most recent analyses of the phase III SPARC trial comparing satraplatin and prednisone to prednisone alone in the second-line setting for HRPC, and is currently under USFDA review for this indication. Whether satraplatin and prednisone offer an advantage over docetaxel retreatment or other cytotoxic agents in this setting is an unanswered question and worthy of study. Investigation of predictors of platinum sensitivity and the use of satraplatin in patients with neuroendocrine subsets of metastatic prostate cancer may be warranted given the advances in biomarker and genomic technology and the known sensitivity of small cell cancers to platinum agents. Further study of satraplatin alone or in combination with docetaxel or other molecular and chemotherapeutic agents seems warranted to improve on current outcomes.

No MeSH data available.


Related in: MedlinePlus